Breathtec Biomedical Inc. will undergo a 2-for-1 consolidation of its common shares pursuant to its acquisition agreement with NASH Pharmaceuticals Inc.

The Vancouver, British Columbia-based company, which is registered with the Canadian Securities Exchange, will begin trading on a post-consolidated basis from Oct. 17, according to a press release.

Breathtec Biomedical's issued and outstanding common shares will reduce from 57,897,356 to 28,948,678.

The company develops breath-analysis technology for the early screening of life-threatening diseases.